CLLS vs. SCLX, MOLN, CRDL, DBVT, VXRT, OMGA, VCXB, CGEN, OTLK, and KOD
Should you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Scilex (SCLX), Molecular Partners (MOLN), Cardiol Therapeutics (CRDL), DBV Technologies (DBVT), Vaxart (VXRT), Omega Therapeutics (OMGA), 10X Capital Venture Acquisition Corp. III (VCXB), Compugen (CGEN), Outlook Therapeutics (OTLK), and Kodiak Sciences (KOD). These companies are all part of the "biological products, except diagnostic" industry.
Scilex (NASDAQ:SCLX) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, community ranking, media sentiment and analyst recommendations.
Cellectis received 400 more outperform votes than Scilex when rated by MarketBeat users. However, 100.00% of users gave Scilex an outperform vote while only 68.24% of users gave Cellectis an outperform vote.
In the previous week, Scilex and Scilex both had 4 articles in the media. Scilex's average media sentiment score of 0.95 beat Cellectis' score of 0.48 indicating that Cellectis is being referred to more favorably in the news media.
Cellectis has lower revenue, but higher earnings than Scilex. Cellectis is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.
69.7% of Scilex shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 8.7% of Scilex shares are owned by company insiders. Comparatively, 16.4% of Cellectis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Scilex currently has a consensus target price of $6.00, indicating a potential upside of 704.94%. Cellectis has a consensus target price of $8.50, indicating a potential upside of 177.78%. Given Cellectis' higher possible upside, research analysts clearly believe Scilex is more favorable than Cellectis.
Scilex has a net margin of -244.60% compared to Scilex's net margin of -1,087.66%. Cellectis' return on equity of 0.00% beat Scilex's return on equity.
Scilex has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.08, suggesting that its stock price is 208% more volatile than the S&P 500.
Summary
Scilex beats Cellectis on 8 of the 15 factors compared between the two stocks.
Get Cellectis News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellectis Competitors List
Related Companies and Tools
